Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• When Nighttime Breathing Disrupts Metabolic Health

  Sleep-disordered breathing is increasingly recognized as a systemic health concern rather than an isolated nighttime complaint. Repeated pauses in breathing, shallow airflow, and frequent arousals can alter oxygen levels, sympathetic activity, hormone balance, and cardiovascular function.

  These changes are closely connected with obesity, insulin resistance, hypertension, abnormal lipid levels, and other features of metabolic syndrome. Understanding the relationship helps respiratory specialists, primary care clinicians, and patients identify risk earlier and choose more effective treatment strategies.

  For a respiratory medicine congress associated with APSR and KATRD, this topic sits at the intersection of pulmonology, sleep medicine, endocrinology, and cardiology. It also highlights why multidisciplinary care is essential when breathing problems and metabolic disease occur together.

  Why These Conditions Intersect

  Obstructive sleep apnea is the most common form of sleep-disordered breathing linked to metabolic dysfunction. During sleep, repeated upper-airway collapse causes intermittent hypoxemia and brief awakenings. Even when the patient does not remember waking, these events fragment normal sleep architecture and place stress on the body.

  Excess body weight can increase fat deposits around the neck and upper airway, reducing airway stability. Abdominal obesity may also impair respiratory mechanics and lower functional residual capacity. The relationship is bidirectional: poor sleep and untreated apnea may encourage weight gain, appetite changes, and reduced physical activity, making metabolic control more difficult.

  Biological Pathways Behind the Risk

  Intermittent hypoxia activates the sympathetic nervous system, which can raise heart rate and blood pressure. Repeated oxygen desaturation may also promote oxidative stress and low-grade inflammation. These processes can interfere with vascular function and contribute to the development of hypertension and atherosclerotic disease.

  Sleep fragmentation affects glucose regulation through changes in cortisol, catecholamines, and appetite-related hormones. Insulin sensitivity may decline, while hunger signals become stronger and satiety signals weaker. Over time, this combination can support weight gain and increase the likelihood of prediabetes or type 2 diabetes.

  The clinical picture is not limited to obstructive apnea. Central sleep apnea, obesity hypoventilation syndrome, and sleep-related hypoxemia may also appear in patients with complex cardiometabolic disease. Careful assessment is important because the correct treatment depends on the underlying breathing pattern and associated conditions.

  Recognizing the Clinical Pattern

  Loud snoring, witnessed pauses, gasping, morning headaches, and excessive daytime sleepiness are familiar warning signs. However, some patients present with less obvious symptoms, including resistant hypertension, atrial fibrillation, poor concentration, mood changes, or unexplained fatigue. Women and older adults may be underdiagnosed when classic snoring is absent.

  A waist circumference above a healthy range, elevated fasting glucose, high triglycerides, low HDL cholesterol, and increased blood pressure should heighten clinical suspicion. A patient with several metabolic risk factors and unrefreshing sleep may benefit from sleep evaluation even without severe daytime sleepiness.

  Medical history should include alcohol use, sedating medicines, nasal obstruction, smoking, cardiovascular disease, and family history. Physical examination can assess body mass index, neck circumference, craniofacial features, blood pressure, and signs of chronic hypoventilation.

  From Screening to Diagnosis

  Validated questionnaires such as STOP-Bang or the Epworth Sleepiness Scale can support initial risk assessment, but they do not establish a diagnosis. Home sleep apnea testing may be suitable for adults with a high probability of uncomplicated obstructive sleep apnea. In-laboratory polysomnography is preferable when there is suspected central apnea, significant cardiopulmonary disease, neuromuscular weakness, or unexplained hypoxemia.

  Clinicians should interpret the apnea-hypopnea index alongside oxygen desaturation, event duration, sleep position, arousal burden, and comorbidities. Two patients with the same index may have different levels of cardiovascular and metabolic risk. Continuous glucose measurements, lipid testing, blood pressure monitoring, and liver assessment may provide a broader view of the patient’s health.

  Clinical feature	Why it matters	Useful assessment
  Loud snoring or witnessed apneas	Suggests upper-airway obstruction	Sleep history and screening questionnaire
  Resistant or poorly controlled hypertension	May reflect repeated nocturnal sympathetic surges	Office and home blood pressure monitoring
  Central obesity and rising glucose	Indicates cardiometabolic vulnerability	Waist measurement, fasting glucose, HbA1c
  Daytime fatigue or morning headache	May reflect fragmented sleep or nocturnal hypoxemia	Sleep study with oxygen monitoring
  Persistent hypoxemia or hypoventilation	May require evaluation beyond routine apnea testing	Polysomnography and arterial or venous blood gas testing

  Treatment That Addresses the Whole Patient

  Positive airway pressure, particularly continuous positive airway pressure, remains a primary treatment for many patients with moderate or severe obstructive sleep apnea. Consistent use can reduce respiratory events, improve oxygenation, and lower daytime symptoms. Blood pressure benefits are often greatest when adherence is strong and baseline hypertension is significant.

  Weight management should be integrated into care rather than presented as a substitute for immediate apnea treatment. Nutrition counseling, regular physical activity, behavioral support, anti-obesity medication, and bariatric procedures may be appropriate depending on individual risk. Even moderate weight reduction can improve airway collapsibility and glucose control.

  Other options include mandibular advancement devices, positional therapy, upper-airway surgery, and selected implantable therapies. Treatment selection depends on anatomy, disease severity, patient preference, and access. Diabetes, dyslipidemia, hypertension, and cardiovascular disease should be treated concurrently, with follow-up that measures both sleep-related and metabolic outcomes.

  Practical Priorities For Clinical Care

  A coordinated approach can make screening and long-term management more consistent across respiratory and metabolic services.

  • Screen patients with obesity, resistant hypertension, type 2 diabetes, or unexplained daytime fatigue for sleep-disordered breathing.
  • Confirm suspected disease with an appropriate sleep study rather than relying on symptoms alone.
  • Combine airway treatment with nutrition, exercise, weight-management, and cardiometabolic risk reduction.
  • Monitor positive airway pressure adherence, residual events, oxygenation, blood pressure, and glucose over time.
  • Explain that regular treatment is a long-term health intervention, not simply a way to reduce snoring.

  Education is particularly valuable because patients may stop therapy when symptoms improve. Follow-up should address mask comfort, nasal congestion, humidification, sleep schedule, and practical barriers. Shared decision-making often improves sustained use and allows clinicians to adapt treatment before the patient abandons it.

  A Focus For Respiratory Medicine Collaboration

  Sleep-related breathing disorders require communication between pulmonologists, sleep physicians, cardiologists, endocrinologists, dietitians, and primary care teams. Conference programs focused on respiratory medicine can help bring these perspectives together through scientific sessions, clinical case discussions, and invited expert presentations.

  For international delegates attending an APSR and KATRD congress, practical planning is part of a successful professional experience. Information about entry requirements and supporting documentation is available through the visa information page, allowing participants to prepare before travel.

  The broader value of this subject lies in its clinical reach. Improving nocturnal breathing may help patients manage blood pressure, glucose, weight, and cardiovascular risk, while better metabolic health can support respiratory function and treatment adherence.

  Turning Evidence Into Action

  Clinicians can use every encounter involving obesity, hypertension, diabetes, or unexplained fatigue as an opportunity to consider sleep health. Early recognition, objective testing, individualized therapy, and regular follow-up can reduce the burden of untreated apnea and its metabolic consequences.

  Explore the relevant APSR 2022 scientific program, review the perspectives of respiratory and sleep specialists, and apply coordinated screening in clinical practice. Linking nighttime breathing assessment with metabolic care turns a frequently overlooked symptom pattern into a practical opportunity for prevention.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)